<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942084</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00028772</org_study_id>
    <nct_id>NCT00942084</nct_id>
  </id_info>
  <brief_title>A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)</brief_title>
  <official_title>An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phillip Brian Smith</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies.
      Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been
      adequately studied in full-term or premature neonates. HSV is a very serious infection in
      babies &lt;6 months of age and often results in death or profound mental retardation. HSV leads
      to profound mental retardation in young infants because the virus attacks the central nervous
      system.

      The investigators hypothesize that the currently recommended dose of acyclovir is inadequate
      to produce adequate blood levels to combat herpes simplex infection. The investigators
      propose to study acyclovir levels in the blood of babies who are placed on acyclovir to treat
      a suspected HSV infection. This will allow them to determine the appropriate dose in
      premature infants. This is an unmet public health need because it is likely that the drug
      behaves differently in premature infants than it does in term infants and older children.
      Premature babies have more body water and less body tissue. Their kidneys are more immature
      and do not function as well as full term infants. Premature neonates are also at the greatest
      risk from herpes infection because they have poorly functioning immature immune systems.
      Early and appropriate treatment with acyclovir has resulted in improved outcome in term
      infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonatal herpes infection carries a major risk of death if untreated. Prognosis is related to
      disease extent and timing of therapy, making early diagnosis crucial. Mortality in the
      pre-antiviral era was 90% for disseminated disease and 50% for central nervous system (CNS)
      disease. Institution of high-dose (60 mg/kg/day) antiviral therapy with acyclovir has reduced
      mortality to 31% for disseminated disease and 6% for CNS disease.1 Although acyclovir has
      reduced mortality dramatically, morbidity remains high.

      Study population: Infants &lt; 45 days postnatal age, suspected to have a systemic infection
      divided into groups by gestational and postnatal age:

      Group-1: 23-29 weeks gestational age, &lt;14 days postnatal age Group-2: 23-29 weeks gestational
      age, 14-44 days postnatal age Group-3: 30-34 weeks gestational age, &lt;45 days postnatal age

      Intravenous acyclovir will be administered for 3 days.

      Timing of PK sample collection will be with respect to the end of each IV infusion. Timed PK
      sampling will be drawn at doses 1, and doses 5, 6, 7, 8, or 9.

      Dose 1:

      0-15 minutes after completion of the 1st dose; Within 30 minutes prior to administration of
      2nd dose

      Steady state [doses 5 or 6 (groups 1 and 2), doses 8 or 9 (group 3)]:

      Within 30 minutes prior to dose; 0-15 minutes after completion of the dose; 2-3 hours after
      completion of the dose; Within 30 minutes prior to administration of the next dose

      Last dose:

      6-7 hours after the last dose (groups 1 and 2)and 10-11 hours after the last dose (group 3)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>V1:0-5 min,2-4 hrs,6-8 hrs post Doses 1&amp;5-15;prior to doses 5-15; V2:0-15 min post doses 1&amp;5-15; within 30 min prior to doses 2&amp;5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose</time_frame>
    <description>Timeframe:
Version 1:0-5 min,2-4 hrs,6-8 hrs post doses 1 and 5-15; prior to doses 5-15 Version 2:0-15 min post doses 1 and 5-15; within 30 min prior to doses 2 and 5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (V)</measure>
    <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (T1/2)</measure>
    <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Steady State Concentration (Cmaxss)</measure>
    <time_frame>up to 3 dasy of study drug administration and 10 days of safety monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady State Concentration at 50% of the Dosing Interval (C50ss)</measure>
    <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Steady State Concentration (Cminss)</measure>
    <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Herpes Simplex Virus</condition>
  <condition>Neonatal Sepsis</condition>
  <arm_group>
    <arm_group_label>Protocol V2&amp;up-Grp1-Acyclo10 mg/kg IVq12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gestational Age 23-29 weeks Postnatal Age &lt; 14 days Dosage 10 mg/kg IV q12 Number of Infants 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol V2&amp;up-Grp2_Acyclo20 mg/kg IVq12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gestational Age 23-29 weeks Postnatal Age 14-44 days Dosage 20 mg/kg IV q12 Number of Infants 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol V2&amp;up-Grp3-Acyclo20 mg/kg IVq8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gestational Age 30-34 weeks Postnatal Age &lt;45 days Dosage 20 mg/kg IV q8 Number of Infants 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients in protocol V1 were to be dosed with 500 mg/m2 IV q8h. Protocol V1 Group 1: Gestational Age: 23-29 Weeks; PNA: &lt;14 days; Protocol V1 Group 2: Gestational Age: 30-42 Weeks; PNA: &lt;14 days; Protocol V1 Group 3: Gestational Age: 23-29 Weeks; PNA: 14-60 days; Protocol V1 Group 4: Gestational Age: 30-42 Weeks; PNA: 14-60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
    <description>Protocol V2 &amp; up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).
Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).</description>
    <arm_group_label>Protocol V2&amp;up-Grp1-Acyclo10 mg/kg IVq12</arm_group_label>
    <arm_group_label>Protocol V2&amp;up-Grp2_Acyclo20 mg/kg IVq12</arm_group_label>
    <arm_group_label>Protocol V2&amp;up-Grp3-Acyclo20 mg/kg IVq8</arm_group_label>
    <arm_group_label>Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The investigator or other study site personnel will document in the source documents (e.g.,
        the hospital chart) that informed consent was obtained. Laboratory tests or
        non-pharmacologic treatment procedures that were performed as standard of care within 72
        hours prior to first dose of study drug may be used for screening procedures and recorded
        in the CRF.

        Inclusion Criteria

          1. &lt; 45 days of age at the time of initial study drug administration.

          2. Sufficient venous access to permit administration of study medication.

          3. Availability and willingness of the parent/legal guardian to provide written informed
             consent.

          4. Suspected HSV sepsis OR At least two (2) of the following

               -  Signs of sepsis AND negative blood cultures for &gt;24 hours7

               -  Respiratory distress8

               -  Lethargy8

               -  Fever ≥ 38.0°C7

               -  Skin lesions7,8

               -  Seizures (clinical OR EEG confirmed)7

               -  Irritability7

               -  AST OR ALT &gt;2 X upper limit of normal7,8

               -  &gt;20 WBCs/µL or &gt;500 RBCs/µL7

        Exclusion Criteria

          1. History of anaphylaxis attributed to acyclovir.

          2. Serum creatinine &gt;1.7 mg/dL.

          3. Urine output &lt;0.5 mL/kg/hour over the previous 12 hours

          4. Previous participation in the study.

          5. Concomitant condition, which in the opinion of the investigator would preclude a
             participant's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip B Smith, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wesely Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-4976</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Whitley RJ. Herpes simplex virus infection. Semin Pediatr Infect Dis. 2002 Jan;13(1):6-11. Review.</citation>
    <PMID>12118847</PMID>
  </reference>
  <reference>
    <citation>Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Weller S, Soong SJ, Kiell J, Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001 Aug;108(2):230-8.</citation>
    <PMID>11483782</PMID>
  </reference>
  <reference>
    <citation>Lietman PS. Acyclovir clinical pharmacology. An overview. Am J Med. 1982 Jul 20;73(1A):193-6. Review.</citation>
    <PMID>7048912</PMID>
  </reference>
  <reference>
    <citation>Englund JA, Fletcher CV, Balfour HH Jr. Acyclovir therapy in neonates. J Pediatr. 1991 Jul;119(1 Pt 1):129-35.</citation>
    <PMID>2066845</PMID>
  </reference>
  <reference>
    <citation>Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982 Jul 20;73(1A):186-92. Review.</citation>
    <PMID>7048911</PMID>
  </reference>
  <reference>
    <citation>Hintz M, Connor JD, Spector SA, Blum MR, Keeney RE, Yeager AS. Neonatal acyclovir pharmacokinetics in patients with herpes virus infections. Am J Med. 1982 Jul 20;73(1A):210-4.</citation>
    <PMID>6285713</PMID>
  </reference>
  <reference>
    <citation>Yeager AS. Use of acyclovir in premature and term neonates. Am J Med. 1982 Jul 20;73(1A):205-9.</citation>
    <PMID>6285712</PMID>
  </reference>
  <reference>
    <citation>Pickering LK. Red Book. 28th ed. Elk Grove Village, Illinois: American Academy of Pediatrics; 2009.</citation>
  </reference>
  <reference>
    <citation>Kimberlin DW. When should you initiate acyclovir therapy in a neonate? J Pediatr. 2008 Aug;153(2):155-6. doi: 10.1016/j.jpeds.2008.04.027.</citation>
    <PMID>18639724</PMID>
  </reference>
  <reference>
    <citation>Brigden D, Bye A, Fowle AS, Rogers H. Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection. J Antimicrob Chemother. 1981 Apr;7(4):399-404.</citation>
    <PMID>7251524</PMID>
  </reference>
  <reference>
    <citation>Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis. 1988 Feb;157(2):385-8.</citation>
    <PMID>3335815</PMID>
  </reference>
  <results_reference>
    <citation>Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009 Jan;24(1):67-76. doi: 10.1007/s00467-008-0997-5. Epub 2008 Oct 10.</citation>
    <PMID>18846389</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2009</study_first_submitted>
  <study_first_submitted_qc>July 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <results_first_submitted>August 27, 2013</results_first_submitted>
  <results_first_submitted_qc>November 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2014</results_first_posted>
  <last_update_submitted>November 19, 2013</last_update_submitted>
  <last_update_submitted_qc>November 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Phillip Brian Smith</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>HSV</keyword>
  <keyword>Acyclovir</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Neonate</keyword>
  <keyword>Premature</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total enrollment is 32. 32 for safety analysis and 30 in PK population (28 included in final PK analysis).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Acyclovir Study Enrollment</title>
          <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30">There were 2 infant deaths. None determined to be related to study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acyclovir Study Design</title>
          <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Postnatal Age (days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" lower_limit="0.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Gestational Age (weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.5" lower_limit="23.0" upper_limit="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birthweight</title>
          <units>grams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1295" lower_limit="420" upper_limit="4840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clearance (CL)</title>
        <description>Timeframe:
Version 1:0-5 min,2-4 hrs,6-8 hrs post doses 1 and 5-15; prior to doses 5-15 Version 2:0-15 min post doses 1 and 5-15; within 30 min prior to doses 2 and 5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose</description>
        <time_frame>V1:0-5 min,2-4 hrs,6-8 hrs post Doses 1&amp;5-15;prior to doses 5-15; V2:0-15 min post doses 1&amp;5-15; within 30 min prior to doses 2&amp;5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose</time_frame>
        <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Study Design</title>
            <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL)</title>
          <description>Timeframe:
Version 1:0-5 min,2-4 hrs,6-8 hrs post doses 1 and 5-15; prior to doses 5-15 Version 2:0-15 min post doses 1 and 5-15; within 30 min prior to doses 2 and 5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose</description>
          <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
          <units>L/h/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.278" lower_limit="0.095" upper_limit="0.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (V)</title>
        <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
        <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Study Design</title>
            <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (V)</title>
          <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
          <units>L/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" lower_limit="0.293" upper_limit="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life (T1/2)</title>
        <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
        <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Study Design</title>
            <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (T1/2)</title>
          <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.07" lower_limit="1.61" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Steady State Concentration (Cmaxss)</title>
        <time_frame>up to 3 dasy of study drug administration and 10 days of safety monitoring</time_frame>
        <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Study Design</title>
            <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Steady State Concentration (Cmaxss)</title>
          <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="4.59" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Steady State Concentration at 50% of the Dosing Interval (C50ss)</title>
        <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
        <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Study Design</title>
            <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Concentration at 50% of the Dosing Interval (C50ss)</title>
          <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" lower_limit="3.38" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Steady State Concentration (Cminss)</title>
        <time_frame>up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
        <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acyclovir Study Design</title>
            <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Steady State Concentration (Cminss)</title>
          <population>32 infants enrolled. 2 infants died. 2 infants did not contribute PK samples to the analysis. 28 contributed PK samples to the final analysis.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="2.19" upper_limit="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 days of study drug administration and 10 days of safety monitoring</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acyclovir Study Design</title>
          <description>Two open-label PK studies contributed the data for this report. Version 1 was single-center and Version &gt;=2 was multi-center. Acyclovir was administered intravenously as a 1-hour infusion for up to 3 days. Dosing in Study 1 was 500 mg/m2 every 8 hours. Dosing in Study 2 was determined by GA and PNA: 10 mg/kg every 12 hours (23-29 weeks GA and &lt;14 days PNA); 20 mg/kg every 12 hours (23-29 weeks GA and 14-44 days PNA); and 20 mg/kg every 8 hours (30-34 weeks GA and &lt;45 days PNA).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>1 infant died due to nonketotic hyperglycinaemia and 1 infant dies due to sepsis.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemolytic anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Congenital cardiovascular anomaly</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nonketotic hyperglycinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Neonatal hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intraventricular haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chronic respiratory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Infantile apnoeic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>P. Brian Smith, MD MPH MHS</name_or_title>
      <organization>Duke Clinical Research Institute</organization>
      <phone>919-668-8951</phone>
      <email>brian.smith@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

